Table 4.
Baseline Subject Characteristics by FSH Tertiles in 188 Premenopausal Women Diagnosed With Breast Cancer and Treated With Adjuvant Chemotherapy
| FSH Range in Each Tertile |
P Value | |||
|---|---|---|---|---|
| 0–21.1 IU/L (n = 68) | 21.2–61.6 IU/L (n = 67) | 61.7–124.6 IU/L (n = 67) | ||
| Age (y) | 42.6 ± 6.2 | 46.8 ± 5.4 | 47.6 ± 4.5 | <.001 |
| Weight (kg) | 71.0 ± 18.5 | 70.1.0 ± 18.2 | 71.0 ± 18.5 | .08 |
| Height (cm) | 163.3 ± 7.0 | 163.2 ± 7.4 | 161.2 ± 10.6 | NS |
| BMI (kg/m2) | 26.6 ± 6.4 | 26.3 ± 6.9 | 25.2 ± 5.4 | NS |
| LS BMD (g/cm2) | 1.023 ± 0.130 | 1.001 ± 0.098 | 0.979 ± 0.100 | .06 |
| FN BMD (g/cm2) | 0.836 ± 0.010 | 0.793 ± 0.100 | 0.760 ± 0.093 | <.001 |
| Hip BMD (g/cm2) | 0.962 ± 0.115 | 0.939 ± 0.112 | 0.885 ± 0.098 | .002 |
| Menstruating (% yes) | 43% | 6% | 6% | <.001 |
| Tamoxifen (% yes) | 56% | 85% | 39% | <.001 |
| Race | NS | |||
| White | 62% | 72% | 70% | |
| Non-White | 38% | 28% | 30% | |
| Estradiol (pg/mL) | 100.3 ± 78.4 | 89.5 ± 94.1 | 68.5 ± 49.4 | .05 |
| 25-OH D (ng/mL) | 28.8 ± 9.9 | 32.8 ± 13.8 | 37.2 ± 13.6 | <.001 |
| Alkaline phosphatase (U/L) | 66.8 ± 22.8 | 65.7 ± 18.0 | 76.7 ± 28.5 | NS |
| Urinary NTX (nmBCE/mmol Cr) | 53.6 ± 22.1 | 62.4 ± 25.0 | 84.4 ± 45.9 | NS |
| CTX (ng/mL) | 0.49 (0.34–0.67) | 0.56 (0.42–0.75) | 0.75 (0.54–1.11) | <.001 |
| P1NP (ng/mL) | 64.6 ± 29.9 | 59.2 ± 25.2 | 88.6 ± 48.4 | <.001 |
| Osteocalcin (ng/mL) | 21.4 ± 8.0 | 21.5 ± 10.5 | 31.1 ± 13.0 | <.001 |
| iPTH (pg/mL) | 44.3 ± 21.6 | 55.3 ± 44.9 | 38.6 ± 16.4 | .006 |
| 1,25-(OH)2 vitamin D (pg/mL) | 32.7 ± 12.1 | 31.6 ± 10.7 | 30.7 ± 7.9 | NS |
Values are mean ± SD or %; CTX values are median and interquartile range. LS, lumbar spine; CTX, C-terminal telopeptide; NTX, N-terminal telopeptide; P1NP, total procollagen type 1 amino-terminal propeptide; iPTH, intact PTH; BMD, bone mineral density; 1,25-(OH)2 vitamin D, 1,25 dihydroxyvitamin D; NS, not significant. P values are for overall comparisons among tertiles by ANOVA.